Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
Quality of life with Relvar
Improving asthma control has a direct impact on the quality of life of patients, helping them return to doing the things they love to do.
When measured using the Asthma Quality of Life Questionnaire (AQLQ), 27% more patients improved their quality of life vs other commonly used ICS/LABAs in everyday practice.*1
At baseline, the most commonly prescribed ICS/LABAs were:2
- Fluticasone propionate/salmeterol
- Budesonide/formoterol
- Beclomethasone/formoterol
This graph has been independently created by GSK from the original data.
The same results were first published in Svedsater H, et al. Respir Med 2018;141:198–206.
Relvar: superior QoL across all AQLQ domains vs other commonly used ICS/LABAs*1
This graph has been independently created by GSK from the original data. The same results were first published in Svedsater H, et al. Respir Med 2018;141:198–206.
The Asthma Quality of Life Questionnaire (AQLQ) is clinically validated to assess the physical and emotional impact of asthma3
Four health-related quality of life domains are assessed3
Questions are answered on a scale of 1–7, where 7=not impaired, 1=severely impaired. Results are expressed as an average score for each of the four domains and as an overall average.
Symptom-free nights
According to GINA, one of the key indicators of poor asthma control is experiencing night-time symptoms.4 For many patients, this parameter may also impact their quality of life.
In an analysis of three studies comparing Relvar to placebo, fluticasone furoate (FF), and fluticasone propionate (FP) respectively, a higher percentage of patients experienced symptom-free nights with Relvar in all instances.5
This graph has been independently created by GSK from the original data. The same results were first published in Kerwin E, et al. J Asthma 2018;55:890–897. Percentage of patients with 100% symptom-free nights for patients enrolled in Bleecker et al. (A), Bernstein et al. (B), and O’Byrne et al. (C).
Note: Fluticasone furoate (FF) is not licensed as an inhaled therapy
This graph has been independently created by GSK from the original data. The same results were first published in Kerwin E, et al. J Asthma 2018;55:890–897. Percentage of patients with 100% symptom-free nights for patients enrolled in Bleecker et al. (A), Bernstein et al. (B), and O’Byrne et al. (C).
Note: Fluticasone furoate (FF) is not a licensed formulation
This graph has been independently created by GSK from the original data. The same results were first published in Kerwin E, et al. J Asthma 2018;55:890–897. Percentage of patients with 100% symptom-free nights for patients enrolled in Bleecker et al. (A), Bernstein et al. (B), and O’Byrne et al. (C).
Note: Fluticasone furoate (FF) is not a licensed formulation
The long-lasting effects of Relvar
How long do these effects last, and what is it about Relvar molecules that leads to such improvements in the first place?
Discover Relvar
Need help with this product?
Footnotes
*Quality of life was measured by the Asthma Quality of Life Questionnaire at 12 months. A clinically meaningful improvement was defined as an increase from baseline of ≥0.5 units. Data presented are from a subset of patients in the ITT population prescribed ICS/LABA at baseline who were initiated with Relvar or continued on their existing ICS/LABA.
†Analysis of the environmental stimuli domain was pre-planned.
‡Data from a post-hoc analysis.
Abbreviations
AQLQ, Asthma Quality of Life Questionnaire; CI, confidence interval; FF, fluticasone furoate; FP, fluticasone propionate; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; ITT, intention-to-treat; LABA, long-acting β2-agonist; OD, once daily; OR, odds ratio; QoL, quality of life; VI, vilanterol.
References
- Svedsater H, et al. Respir Med 2018;141:198–206.
- GSK clinical study report. HZA115150; 2017. Accessed June 2023.
- Juniper EF, et al. J Clin Epidemiol 1994;47:81–87.
- GINA. Global strategy for asthma management and prevention, 2020. Available at: www.ginasthma.org. Accessed June 2023.
- Kerwin E, et al. J Asthma 2018;55:890–897.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230007 June 2023
